RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer — Stella

Home/Pancreatic Ductal Adenocarcinoma (PDAC)/

View on ClinicalTrials.gov

Recruiting

Back to Pancreatic Ductal Adenocarcinoma (PDAC) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

France

Damien JOLLY, Reims

Key details

Sponsor

CHU de Reims

Enrollment target

~90 participants

Started

October 2021

Primary completion

October 2026

Age range

18 Years and older

Last updated November 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.